Safety and efficacy of osilodrostat (LCI699) for the treatment of patients with Cushing's disease

Mise à jour : Il y a 4 ans
Référence : EUCTR2013-004766-34

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

To compare the complete response rate at the end of the 8-week period of randomized withdrawal (Week 34) between patients randomized to continued LCI699 therapy vs. placebo.


Critère d'inclusion

  • Cushing's disease